Docoh
Loading...

UTHR United Therapeutics

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Company profile

Ticker
UTHR
Exchange
CEO
Martine Rothblatt
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
521984749

UTHR stock data

(
)

Calendar

24 Feb 21
12 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
7 Apr 21 Dwek Raymond Common Stock Sale back to company Dispose D No Yes 191.1 2,000 382.2K 0
7 Apr 21 Dwek Raymond Common Stock Option exercise Aquire M No Yes 54.77 2,000 109.54K 2,000
7 Apr 21 Dwek Raymond Share Tracking Award Common Stock Option exercise Dispose M No Yes 54.77 2,000 109.54K 8,000
1 Apr 21 Olian Judy D. Common Stock Sell Dispose S No Yes 184.96 4,207 778.13K 5,790
1 Apr 21 Olian Judy D. Common Stock Option exercise Aquire M No Yes 76.36 4,207 321.25K 9,997
1 Apr 21 Olian Judy D. Stock Options Common Stock Option exercise Dispose M No Yes 76.36 4,207 321.25K 0
1 Apr 21 Mahon Paul A Common Stock Sale back to company Dispose D No Yes 192.34 6,000 1.15M 36,369
1 Apr 21 Mahon Paul A Common Stock Option exercise Aquire M No Yes 94.96 6,000 569.76K 42,369
1 Apr 21 Mahon Paul A Share Tracking Award Common Stock Option exercise Dispose M No Yes 94.96 6,000 569.76K 47,500
26 Mar 21 Kurzweil Ray Common Stock Sale back to company Dispose D No No 171.21 3,750 642.04K 7,540

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

95.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 348 325 +7.1%
Opened positions 68 44 +54.5%
Closed positions 45 58 -22.4%
Increased positions 97 120 -19.2%
Reduced positions 136 114 +19.3%
13F shares
Current Prev Q Change
Total value 6.47B 4.19B +54.4%
Total shares 42.56M 41.47M +2.6%
Total puts 100.8K 58K +73.8%
Total calls 246.9K 113K +118.5%
Total put/call ratio 0.4 0.5 -20.5%
Largest owners
Shares Value Change
BLK Blackrock 4.27M $648.62M -0.8%
Vanguard 3.96M $601.7M +2.1%
Renaissance Technologies 3.61M $547.55M -2.7%
Avoro Capital Advisors 2.85M $432.6M NEW
FMR 2.32M $352.56M -9.6%
STT State Street 1.54M $233.68M +2.0%
Acadian Asset Management 1.13M $171.22M -11.0%
Dimensional Fund Advisors 886.33K $134.53M -1.8%
First Trust Advisors 846.8K $128.54M -0.1%
Adage Capital Partners GP, L.L.C. 825K $125.23M -29.8%
Largest transactions
Shares Bought/sold Change
Avoro Capital Advisors 2.85M +2.85M NEW
Consonance Capital Management 528.96K +528.96K NEW
Great Point Partners 150K -490.77K -76.6%
Norges Bank 388.33K +388.33K NEW
Adage Capital Partners GP, L.L.C. 825K -350K -29.8%
Aqr Capital Management 624.2K -318.85K -33.8%
Ensign Peak Advisors 48.18K -261.87K -84.5%
FMR 2.32M -245.33K -9.6%
Two Sigma Advisers 0 -244.6K EXIT
Nuveen Asset Management 497.56K -232.32K -31.8%

Financial report summary

?
Management Discussion
  • This section of this Report generally discusses 2020, 2019, and 2018 items and year-to-year comparisons between 2020 and 2019. Discussions of year-to-year comparisons between 2019 and 2018 that are not included in this Report can be found in Part II, Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations of our Form 10-K filed on February 26, 2020 (our 2019 Annual Report).
  • Net product sales from our treprostinil-based products (Remodulin, Tyvaso, and Orenitram) grew by $65.2 million in 2020, as compared to 2019. This increase was driven by growth in U.S. net product sales from our treprostinil-based products of $122.6 million in 2020, as compared to 2019, partially offset by a decline in net product sales outside the U.S. from our treprostinil-based products of $57.4 million, as compared to 2019.
  • Remodulin net product sales decreased in 2020 as compared to 2019, driven by a $56.6 million decrease in sales outside the United States, primarily due to a decline in quantities sold, which we believe resulted from generic competition and the impact of COVID-19. U.S. Remodulin net product sales decreased by $13.7 million, as compared to 2019, which we believe primarily resulted from a reduction in new patient prescriptions and new patient starts that we experienced in the second quarter of 2020 due to the impact of COVID-19, as described above under Impact of COVID-19 on our Business.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abatacept, abundance, accessibility, acknowledging, add, Addressedthe, ADR, aggravate, ample, antifibrotic, aseptic, assignor, atmosphere, attain, Attorney, awaiting, back, belief, belumosudil, bidding, Biden, Biomedical, Biopharma, Biotech, Bipartisan, Boehringer, bone, borne, Brexit, Bristol, bulk, busy, bylaw, capability, capable, Carlo, caution, cautionary, CCPA, cellularize, Chancery, charitable, childcare, choice, CHP, Coalition, concomitant, conferencing, confirmed, Congressional, constantly, contact, Contractor, coordinating, copayment, COPD, cope, CorporationIndex, correlated, coupled, CRL, crucial, CVC, cybersecurity, Danyelza, de, deadline, decade, declassification, DEI, Denko, diagnostic, dismissed, disproportionate, diversification, Dohme, downturn, DPI, duty, economy, Emerging, endorsement, England, enjoined, enrich, Esbriet, estoppel, ethnic, exacerbated, excellence, exiting, exponential, extinguish, Facebook, FCP, FDASIA, FDCA, feel, feeling, Ferrer, FibroGen, fibrosing, fibrotic, field, fifteen, fILD, firmly, footnote, forum, foster, freight, FSS, fullest, FVC, Galecto, GDPR, GmbH, great, Grupo, hall, hard, heightened, hindered, HIPAA, Holistic, home, HRSA, Humana, hypersensitivity, identification, IIP, ILD, imputation, inapplicable, incident, incomplete, indefinite, Ingelheim, inOur, instilled, instrument, intact, interact, Internacional, ISR, Journal, judge, justify, Kadmon, landscape, language, Latin, lessen, Liminal, Linda, lodge, LP, malfunction, malfunctioned, marketplace, marrow, Maxwell, MDRP, MediciNova, mental, Merck, misreporting, misrepresentation, missing, mission, Monte, mounting, moved, MSP, MSPA, Neck, nintedanib, Nitto, nonclinical, novo, nurse, nursing, NV, ofEquity, Ofev, ofthe, omitted, Orencia, overcharge, overcharging, overcome, overshadow, owed, palmitil, pamrevlumab, pandemic, passion, passionately, pause, paused, peer, Pemziviptadil, pervasive, pirfenidone, PMPI, precautionary, precipitate, prepay, prevalent, prioritization, prioritized, proactive, proud, purification, purported, pursuit, qui, racial, Racketeer, Radford, rapidly, recalculate, recalculation, recombinant, recommenced, recordkeeping, recoup, recruit, recruiting, recruitment, regular, remanded, repeated, repurpose, resource, resume, retroactive, rewrite, rigorously, RLD, robust, safeguarding, safest, segregated, sense, sequestration, Seralutinib, Sharpe, shielding, shut, simulation, situation, SK, smart, sNDA, solid, sonic, speak, specialist, Speed, Squibb, steadily, stringent, strive, strongly, Sumitovant, sunset, Sunshine, supervisory, Surgeon, surveillance, tam, Task, telemedicine, TETON, thereunder, thrive, tipelukast, today, top, town, TPIP, transportation, travel, Tricare, Turkey, turnover, ultra, unaffected, unannounced, unclassified, unconsolidated, unconstitutional, undergone, undermine, undertaken, undisclosed, UnitedHealth, Unitherian, unprecedented, unpredictable, untitled, VA, vaccine, Veteran, vial, VirginiaFebruary, visit, vital, waiting, waived, Warp, Wisconsin, Women, workforce, workplace, worth, Zone
Removed: AB, acceleration, accident, admission, aggressively, ASR, attracting, authorizing, Bardoxolone, borrowing, CEO, chest, chose, Citibank, companywide, compound, concession, consulting, continually, convertible, counterparty, crystal, DB, debarment, declared, departed, depot, desired, Deutsche, devote, disgorgement, donut, drop, dynamic, engineered, enhance, estate, familiarized, favor, forfeiture, fulfilled, gel, harming, hole, implied, incremental, incrementally, introduce, investigated, jointly, Junior, leukoencephalopathy, London, mandatorily, Mark, narrow, negotiate, noncompetitive, observe, obsolete, overseeing, porcine, posterior, promised, real, Reata, reclassify, redeemable, redemption, render, repaid, repealed, requesting, retaining, scrutinizing, skilled, staggered, strike, subjecting, subpoena, succession, transverse, Unaudited, unaware, unfavorably, urinary, validate, vein, viability